Table 4.

Relative hazard according to the number of elevated serum markers (n = 64).

Variable	Number of elevated markers	No. of patients	Univariate analysis			Multivariate analysis
			Relative hazard	95% CI	P-value*	Relative hazard	95% CI	P-value*
Serum endocan and AFP	0	13	1			1
	1	34	4.22	0.55-32.62	0.168	2.66	0.32-21.99	0.364
	2	17	21.90	2.82-170.29	0.003	12.07	1.41-103.66	0.023
Serum endocan and DCP	0 or 1	29	1			1
	2	35	4.06	1.75-9.39	0.001	4.26	1.63-11.14	0.003
Serum endocan, AFP, and DCP	0 or 1	24	1			1
	2	24	2.19	0.78-6.17	0.137	1.90	0.64-5.62	0.246
	3	16	14.63	4.82-44.43	<0.0001	10.31	2.64-40.23	0.001

CI, confidence interval; AFP, α-fetoprotein; DCP, des-γ-carboxy prothrombin.

* Cox proportional hazard model. Variables assessed in the multivariate analysis included age (< 70 years vs. ≥ 70 years), gender (female vs. male), etiology of liver disease (non-viral vs. viral), tumor stage (stage I/II vs. III/IV), Child-Pugh grade (A vs. B/C), treatment option, and number of elevated markers.